v3.26.1
Segment Information - Schedule of Financial Data for Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Research and development expenses $ 13,844   $ 16,182   $ 29,010 $ 31,596
General and administrative expenses 4,824   6,467   9,560 12,715
Net loss (17,964) $ (19,042) (21,006) $ (19,680) (37,006) (40,686)
Reportable Segment            
Segment Reporting [Line Items]            
General and administrative expenses 4,824   6,467   9,560 12,715
Other segment items [1] (704)   (1,643)   (1,564) (3,625)
Net loss (17,964)   (21,006)   (37,006) (40,686)
ACR-368 | Reportable Segment            
Segment Reporting [Line Items]            
Research and development expenses 5,637   7,013   11,733 13,660
ACR-2316 | Reportable Segment            
Segment Reporting [Line Items]            
Research and development expenses 1,231   1,766   2,713 2,930
Other Drug Discovery Programs | Reportable Segment            
Segment Reporting [Line Items]            
Research and development expenses 282   564   866 1,208
Personnel | Reportable Segment            
Segment Reporting [Line Items]            
Indirect research and development expenses 5,558   5,478   11,145 11,152
Facilities Supplies And Other | Reportable Segment            
Segment Reporting [Line Items]            
Indirect research and development expenses $ 1,136   $ 1,361   $ 2,553 $ 2,646
[1] Other segment items consist of interest income and other expense, net. Interest income consists of interest income earned on cash equivalents and investments and amortization of premiums and accretion of discounts to maturity for available-for-sale debt securities. Other expense, net primarily consists of realized and unrealized gains and losses on foreign currency transactions, state and franchise taxes, and investment management fees.